Literature DB >> 10808280

[Pulmonary infection caused by Mycobacterium gordonae in immunocompetent patient].

Y Fujita1, H Matsumoto, T Fujikane, S Nakao, N Sasaki, M Takahashi, K Sato, A Takeda, Y Yamazaki, K Tobise.   

Abstract

We report a case of 67-year-old female immunocompetent patient admitted to our hospital because of hemoptysis. Computed tomography (CT) of the lung showed bronchiectasis in the right S5 and small nodules in the right S6 and left S5. The cultures of sputum and bronchial washing specimen repeatedly revealed acid-fast bacilli identified as Mycobacterium gordonae (M. gordonae) by DNA-DNA hybridization (DDH) method. Thus, she was diagnosed to be infected with M. gordonae. She was treated with isoniazid, rifampicin, ethambutol and streptomycin. After treatment, the cultures of sputum and bronchial washing specimen converted to negative, and the chest CT showed improvement of small nodules. M. gordonae is a nontuberculous mycobacterium of very low pathogenic potency. Recently there have been a few reports of infection by M. gordonae not only in immunocompromised patients but also in immunocompetent patients. These cases were considered to be sensitive to initial standard antimycobacterial therapy, therefore, it is important to examine for M. gordonae in cases suspected of nontuberculous mycobacterial infection.

Entities:  

Mesh:

Substances:

Year:  2000        PMID: 10808280

Source DB:  PubMed          Journal:  Kekkaku        ISSN: 0022-9776


  2 in total

1.  Heterogeneity of RNA polymerase gene (rpoB) sequences of Mycobacterium gordonae clinical isolates identified with a DNA probe kit and by conventional methods.

Authors:  Saotomo Itoh; Yuko Kazumi; Chiyoji Abe; Mitsuyoshi Takahashi
Journal:  J Clin Microbiol       Date:  2003-04       Impact factor: 5.948

2.  Completion pneumonectomy after fenestration for empyema due to nontuberculous mycobacteriosis associated with destroyed lung as a result of cancer surgery.

Authors:  Ryo Takahashi; Taiki Fujiwara; Hisami Yamakawa
Journal:  J Thorac Dis       Date:  2017-11       Impact factor: 2.895

  2 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.